Curis, founded in Lexington, United States, is dedicated to developing innovative cancer therapies through its proprietary signaling pathway drug technologies. The company's mission is to create targeted small molecule drug candidates that can effectively treat various forms of cancer. Curis focuses on advancing its drug development efforts, particularly with its lead candidate Emavusertib, aimed at treating hematologic malignancies and other cancers.
Notable individuals affiliated with Curis include its experienced leadership team and scientific advisors, who bring a wealth of expertise in oncology and drug development. The company has garnered investment from prominent biotech investors, contributing to its research and development initiatives. Curis has achieved significant milestones in clinical trials and regulatory progress, making a substantial impact on the field of targeted cancer therapies.
